No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Presence of regression is a favourable prognostic factor for patients with stage I and II cutaneous melanoma

byTeddy Guo

December 31, 2020

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract DIVERSITY trial: Dabigatran etexilate was non-inferior to standard of care in effectively treating acute venous thromboembolism (VTE) in children

RelatedReports

The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing

August 28, 2025

Significant reduction in prostate screening rates after revised guidelines

Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025

“No Evidence of Disease Activity” may be useful goal in multiple sclerosis

Chronic Disease

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

February 24, 2025

Increased risk of subsequent melanoma after first melanoma diagnosis

Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024

Global estimates show one third of the population may benefit from rehabilitation services

Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men

Rosuvastatin therapy for people with HIV not associated with decreased biomarkers of inflammation and immune activation

#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma (bortezomib, lenalidomide, and dexamethasone)

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports